The Review of Compared Progestins Type and Dose Utility against the Pituitary Suppression during Ovarian Stimulation for Assisted Reproductive Technology

1. Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4, p CD001750. doi:10.1002/14651858.CD001750.pub4 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27126581.Search in Google Scholar

2. Dong J, Wang Y, Chai WR, Hong QQ, Wang NL, Sun LH, Kuang HP. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG. 2017;124(7):1048-1055. doi:10.1111/1471-0528.14622 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28276192.10.1111/1471-0528.1462228276192Search in Google Scholar

3. Ubaldi FM, Capalbo A, Vaiarelli A, Cimadomo D, Colamaria S, Alviggi C, Rienzi L. Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertil Steril. 2016;105(6):1488-1495 e1481. doi:10.1016/j.fertnstert.2016.03.002 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27020168.10.1016/j.fertnstert.2016.03.00227020168Search in Google Scholar

4. Zhu X, Ye H, Fu Y. The Utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments. Medicine (Baltimore. 2016;95(28):e4193. doi:10.1097/MD.0000000000004193 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27428219.10.1097/MD.0000000000004193495681327428219Search in Google Scholar

5. Zhu X, Ye H, Fu Y. Comparison of neonatal outcomes following progesterone use during ovarian stimulation with frozen-thawed embryo transfer. Sci Rep. 2017;7(1):7835. doi:10.1038/s41598-017-08472-2 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28798414.10.1038/s41598-017-08472-2555282428798414Search in Google Scholar

6. Yildiz S, Turkgeldi E, Angun B, Eraslan A, Urman B, Ata, B. Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology. Fertil Steril. 2019;112(4):677-683. doi:10.1016/j.fertnstert.2019.06.009 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/31371053.10.1016/j.fertnstert.2019.06.00931371053Search in Google Scholar

7. Zhu X, Ye H, Fu Y. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertil Steri. 2017;108(3):505-512 e502. doi:10.1016/j.fertnstert.2017.06.017 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28697910.10.1016/j.fertnstert.2017.06.01728697910Search in Google Scholar

8. Guo YC, Chen PY, Li TT, Jia L, Sun P, Zhu WS. Liang X. Y. Different progestin-primed ovarian stimulation protocols in infertile women undergoing in vitro fertilization/intracytoplasmic sperm injection: an analysis of 1188 cycles. Arch Gynecol Obstet. 2019;299(4):1201-1212. doi:10.1007/s00404-019-05065-4 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30852654.10.1007/s00404-019-05065-430852654Search in Google Scholar

9. Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J, Ai A. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018;33(2):229-237. doi:10.1093/humrep/dex367 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29300975.10.1093/humrep/dex36729300975Search in Google Scholar

10. Zhu X, Ye H, Fu Y. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a “freeze all” strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertil Steril. 2017;107(2):379-386 e374. doi:10.1016/j.fertnstert.2016.10.030 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27865446.10.1016/j.fertnstert.2016.10.03027865446Search in Google Scholar

11. Evans MB, Parikh T, DeCherney AH, Csokmay JM, Healy, MW, Hill MJ. Evaluation of the cost-effectiveness of ovulation suppression with progestins compared with GnRH analogs in assisted reproduction cycles. Reprod Biomed Online. 2019;38(5):691-698. doi:10.1016/j.rbmo.2018.12.044 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30926176.10.1016/j.rbmo.2018.12.04430926176Search in Google Scholar

12. Iwami N, Kawamata M, Ozawa N, Yamamoto T, Watanabe E, Moriwaka O, Kamiya H. (2018). New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch Gynecol Obstet. 2018;298(3):663-671. doi:10.1007/s00404-018-4856-8 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30069600.Search in Google Scholar

13. La Marca A, Capuzzo M. Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era? Reprod Biomed Online. 2019;39(2):321-331. doi:10.1016/j.rbmo.2019.03.212 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/31138494.10.1016/j.rbmo.2019.03.21231138494Search in Google Scholar